ArticleMedicine2026
Mapping mitochondria-associated research in inflammatory bowel disease: A bibliometric and network analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondria-associated research has become increasingly prominent in inflammatory bowel disease (IBD), but its publication growth, collaboration structure, knowledge base, and thematic evolution have not been comprehensively quantified.
methodsWeb of Science Core Collection records published from 2010 through 2025 were retrieved on September 19, 2025. Of 215 candidate records, 112 met prespecified eligibility criteria. The 111 records with complete Full Record and Cited References metadata were used for primary analyses; 1 additional eligible record was included only in an annual-output sensitivity analysis. Bibliometrix/Biblioshiny, VOSviewer 1.6.20, and R were used for descriptive, network, temporal, and robustness analyses.
resultsAnnual output increased significantly (Kendall τ = 0.638, P = .0009; Sen slope = 1.20 publications/year, 95% confidence interval 0.50-1.71), whereas annualized citation impact showed no significant monotonic trend after exclusion of 2025 (Spearman ρ = 0.093, P = .742). China led corresponding-author output (39 articles), while the United States had the highest aggregate citation count (985). Multi-country publications accounted for 35 of 111 articles (31.5%). The largest institutional collaboration component contained 53 organizations in 8 clusters, and the author component contained 15 authors in 2 clusters. The primary author-keyword network included 22 terms, 6 clusters, 90 links, and a total link strength of 181. Mitophagy, mitochondrial dynamics, and machine learning were positioned toward the recent end of the temporal spectrum. Cited-source and cited-reference networks were densely interconnected, indicating a shared multidisciplinary knowledge base.
conclusionMitochondria-associated IBD research expanded substantially during 2010 to 2025, with concentrated geographic leadership, recurrent but uneven international collaboration, and overlapping themes spanning inflammation, epithelial biology, metabolism, mitochondrial quality control, and host-microbiome interactions. The findings provide a reproducible map of the literature but should not be interpreted as evidence of biological causality or discrete mechanistic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.